Sunesis Pharmaceuticals (SNSS) Misses Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
- Nasdaq hits record high as investors focus on earnings
- Oil slips on rising Mideast crude exports, G7 stocks release
- Intel stock slides as TSMC explores Terafab tie-up, analyst flags share losses
- Schneider Electric to acquire PTC for $22.6 billion in all-cash deal
- Five things to watch in markets in the week ahead
Tweet
Share
E-mailGet Alerts SNSS Hot Sheet
Join SI Premium – FREE
Sunesis Pharmaceuticals (NASDAQ: SNSS) reported Q2 EPS of ($0.15), $0.02 worse than the analyst estimate of ($0.13). Revenue for the quarter came in at $854 thousand versus the consensus estimate of $1.21 million.
For earnings history and earnings-related data on Sunesis Pharmaceuticals (SNSS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs sees AI investment adding to European growth in 2026
- Alethia Capital Starts TTM Technologies (TTMI) at Overweight, 'A Unique Proxy Standing for USA PCB'
- Goldman cuts Carl Zeiss Meditec as ‘valuation disconnected from fundamentals’
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
